Maravai LifeSciences (MRVI) Tops Q4 EPS by 1c, Offers Guidance

Maravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of $0.35, $0.01 better than the analyst estimate of $0.34. Revenue for the quarter came in at $204.7 million versus the consensus estimate of $205.38 million.

GUIDANCE:

Maravai LifeSciences sees FY2023 EPS of $0.32-$0.38, versus the consensus of $0.37. Maravai LifeSciences sees FY2023 revenue of $420-460 million, versus the consensus of $433 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Yeti outlines growth targets and financial framework through 2030
• RBC bullish on Kraft Heinz, sees return to growth in 2027